Walmart, Eli Lilly and Company, Intuitive Surgical, UnitedHealth Group, and Abbott Laboratories are the five Medical stocks to watch today, according to MarketBeat’s stock screener tool. Medical ...

Explore Xeris Biopharma's revenue growth, promising pipeline, & thriving products. Learn about their strong outlook & ...

Eli Lilly just scored a major win with its Phase 3 BRAVE-AA-PEDS study. The trial confirmed baricitinib's effectiveness in ...

As VERZENIO gains traction in early-stage treatments and broadens its approved uses, its revenue is expected to keep growing. While the global CDK4/6 inhibitor market remains highly competitive ...

The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs ...

How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...

AbbVie will pay up to $2.2 billion to develop Danish drugmaker Gubra’s obesity drug. AI takes center stage at HIMSS conference gets underway in Vegas.

Novo Nordisk's blockbuster obesity treatment Wegovy mimics a hormone called GLP-1 to tamp down appetite and regulate blood sugar, while Eli Lilly's own ... long-term growth for our company ...

The licensing deal could set the US drugmaker to vie with Eli Lilly & Co. and Novo Nordisk A/S, the current leaders in a market that's expected to reach $130 billion in annual sales by 2030 ...